Your browser doesn't support javascript.
loading
Epidemiology and complications of anaesthesia in the French centres that participated to NECTARINE: A secondary analysis.
Dahmani, Souhayl; Laffargue, Anne; Dadure, Christophe; De Queiroz, Mathilde; Julien-Marsollier, Florence; Michelet, Daphné; Veyckemans, Francis; Amory, Catherine; Ludot, Hugues; Bert, Dina; Godart, Juliette; Laffargue, Anne; Dupont, Hervé; Urbina, Benjamin; Baujard, Catherine; Roulleau, Philippe; Staiti, Giuseppe; Bordes, Maryline; Nouette Gaulain, Karine; Hamonic, Yann; Semjen, François; Jacqmarcq, Olivier; Lejus-Bourdeau, Caroline; Magne, Cécile; Petry, Léa; Ros, Lilica; Zang, Aurélien; Bennis, Mehdi; Coustets, Bernard; Fesseau, Rose; Constant, Isabelle; Khalil, Eliane; Sabourdin, Nada; Audren, Noémie; Descarpentries, Thomas; Fabre, Fanny; Legrand, Aurélien; Druot, Emilie; Orliaguet, Gilles; Sabau, Lucie; Uhrig, Lynn; De La Briere, François; Jonckheer, Karin; Mission, Jean-Paul; Scordo, Lucia; Couchepin, Caroline; Dadure, Christophe; De La Arena, Pablo; Hertz, Laurent; Pirat, Philippe.
Affiliation
  • Dahmani S; French NECTARINE Trial Group, France; Paris Diderot University (Paris VII), Paris, France; Department of Anaesthesia and Intensive Care, Robert Debré University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France; FHU I2-D2, INSERM U1141, Robert Debré University Hospital, Paris, France.
  • Laffargue A; Department of Anaesthesia and Intensive Care, Jeanne de Flandre University Hospital, Lille, France.
  • Dadure C; Department of Anaesthesia and Intensive Care, Lapeyronie University Hospital, Montpellier, France; Institut de Neurosciences de Montpellier, Unité INSERM U1051, Montpellier, France.
  • De Queiroz M; Department of Anaesthesia and Intensive Care, University Hospital of Lyon, Lyon, France.
  • Julien-Marsollier F; French NECTARINE Trial Group, France; Paris Diderot University (Paris VII), Paris, France; Department of Anaesthesia and Intensive Care, Robert Debré University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France; FHU I2-D2, INSERM U1141, Robert Debré University Hospital, Paris, France.
  • Michelet D; French NECTARINE Trial Group, France; Department of Anaesthesia and Intensive Care, Robert Debré University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France; Department of Anaesthesia and Intensive Care, University Hospital of Reims, Reims, France.
  • Veyckemans F; Department of Anaesthesia and Intensive Care, Jeanne de Flandre University Hospital, Lille, France.
  • Amory C; French NECTARINE Trial Group, France; American Memorial Hospital CHU Reims, Reims, France.
  • Ludot H; French NECTARINE Trial Group, France; American Memorial Hospital CHU Reims, Reims, France.
  • Bert D; French NECTARINE Trial Group, France; Department of Anaesthesia and Intensive Care, Jeanne de Flandre University Hospital, Lille, France.
  • Godart J; French NECTARINE Trial Group, France; Department of Anaesthesia and Intensive Care, Jeanne de Flandre University Hospital, Lille, France.
  • Laffargue A; French NECTARINE Trial Group, France; Department of Anaesthesia and Intensive Care, Jeanne de Flandre University Hospital, Lille, France.
  • Dupont H; French NECTARINE Trial Group, France; CHU Amiens Picardie, Amiens, France.
  • Urbina B; French NECTARINE Trial Group, France; CHU Amiens Picardie, Amiens, France.
  • Baujard C; French NECTARINE Trial Group, France; CHU Bicêtre, Le Kremlin-Bicêtre, France.
  • Roulleau P; French NECTARINE Trial Group, France; CHU Bicêtre, Le Kremlin-Bicêtre, France.
  • Staiti G; French NECTARINE Trial Group, France; CHU Bicêtre, Le Kremlin-Bicêtre, France.
  • Bordes M; French NECTARINE Trial Group, France; CHU de Bordeaux, Bordeaux, France.
  • Nouette Gaulain K; French NECTARINE Trial Group, France; CHU de Bordeaux, Bordeaux, France.
  • Hamonic Y; French NECTARINE Trial Group, France; CHU de Bordeaux, Bordeaux, France.
  • Semjen F; French NECTARINE Trial Group, France; CHU de Bordeaux, Bordeaux, France.
  • Jacqmarcq O; French NECTARINE Trial Group, France; CHU de Nantes, Nantes, France.
  • Lejus-Bourdeau C; French NECTARINE Trial Group, France; CHU de Nantes, Nantes, France.
  • Magne C; French NECTARINE Trial Group, France; CHU de Nantes, Nantes, France.
  • Petry L; French NECTARINE Trial Group, France; CHU Nancy, Nancy, France.
  • Ros L; French NECTARINE Trial Group, France; CHU Nancy, Nancy, France.
  • Zang A; French NECTARINE Trial Group, France; CHU Nancy, Nancy, France.
  • Bennis M; French NECTARINE Trial Group, France; CHU Toulouse, Toulouse, France.
  • Coustets B; French NECTARINE Trial Group, France; CHU Toulouse, Toulouse, France.
  • Fesseau R; French NECTARINE Trial Group, France; CHU Toulouse, Toulouse, France.
  • Constant I; French NECTARINE Trial Group, France; Hôpital Armand-Trousseau AP-HP, Paris, France.
  • Khalil E; French NECTARINE Trial Group, France; Hôpital Armand-Trousseau AP-HP, Paris, France.
  • Sabourdin N; French NECTARINE Trial Group, France; Hôpital Armand-Trousseau AP-HP, Paris, France.
  • Audren N; French NECTARINE Trial Group, France; Hôpital couple enfant, CHU Grenoble Alpes, Grenoble, France.
  • Descarpentries T; French NECTARINE Trial Group, France; Hôpital couple enfant, CHU Grenoble Alpes, Grenoble, France.
  • Fabre F; French NECTARINE Trial Group, France; Hôpital couple enfant, CHU Grenoble Alpes, Grenoble, France.
  • Legrand A; French NECTARINE Trial Group, France; Hôpital couple enfant, CHU Grenoble Alpes, Grenoble, France.
  • Druot E; French NECTARINE Trial Group, France; Hôpital Universitaire Necker Enfants Malades, Paris, France.
  • Orliaguet G; French NECTARINE Trial Group, France; Hôpital Universitaire Necker Enfants Malades, Paris, France.
  • Sabau L; French NECTARINE Trial Group, France; Hôpital Universitaire Necker Enfants Malades, Paris, France.
  • Uhrig L; French NECTARINE Trial Group, France; Hôpital Universitaire Necker Enfants Malades, Paris, France.
  • De La Briere F; French NECTARINE Trial Group, France; Fondation Lenval - Hôpital pour enfants, Nice, France.
  • Jonckheer K; French NECTARINE Trial Group, France; Fondation Lenval - Hôpital pour enfants, Nice, France.
  • Mission JP; French NECTARINE Trial Group, France; Fondation Lenval - Hôpital pour enfants, Nice, France.
  • Scordo L; French NECTARINE Trial Group, France; Fondation Lenval - Hôpital pour enfants, Nice, France.
  • Couchepin C; French NECTARINE Trial Group, France; Department of Anaesthesia and Intensive Care, Lapeyronie University Hospital, Montpellier, France.
  • Dadure C; French NECTARINE Trial Group, France; Department of Anaesthesia and Intensive Care, Lapeyronie University Hospital, Montpellier, France.
  • De La Arena P; French NECTARINE Trial Group, France; Department of Anaesthesia and Intensive Care, Lapeyronie University Hospital, Montpellier, France.
  • Hertz L; French NECTARINE Trial Group, France; Department of Anaesthesia and Intensive Care, Lapeyronie University Hospital, Montpellier, France.
  • Pirat P; French NECTARINE Trial Group, France; Department of Anaesthesia and Intensive Care, Lapeyronie University Hospital, Montpellier, France.
Anaesth Crit Care Pain Med ; 41(2): 101036, 2022 04.
Article in En | MEDLINE | ID: mdl-35181529
ABSTRACT

INTRODUCTION:

Neonatal and infant anaesthesia are associated with a high risk of perioperative complications. The aim of the current study was to describe those risks in France using the French data from the NECTARINE study. MATERIAL AND

METHODS:

Data from the French centres that participated to the NECTARINE study were analysed. The primary goal of the study was the description of patients' characteristics, procedures and perioperative management and their comparison with the results of the European NECTARINE study. Secondary outcomes were the description of major perioperative complications and death.

RESULTS:

Overall, 926 procedures collected in 15 centres (all teaching hospitals) were analysed. Comparison between the French and European NECTARINE cohorts found few differences related to patients' characteristics and procedures. The rate of interventions for critical events (respiratory, haemodynamic, and metabolic) was similar between the two cohorts. Near-infrared spectroscopy monitoring was used in 12% of procedures. Nearly none of the thresholds for these interventions met the published standards. By day 30, complications (respiratory, haemodynamic, metabolic, renal, and liver failure) and death were observed in 14.4% [95% CI 11.6-16.4]% and 1.8% [95% CI 1.1-2.9] of cases, respectively.

DISCUSSION:

Although the health status of the patients in the French cohort was less severe, procedures, management and postoperative complications and mortality rates were similar to the European cohort. However, thresholds for interventions were often inadequate in both cohorts. Efforts should be undertaken to improve the knowledge and use of new monitoring devices in this population.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Anesthesia Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies / Screening_studies Aspects: Patient_preference Limits: Humans / Infant / Newborn Country/Region as subject: Europa Language: En Journal: Anaesth Crit Care Pain Med Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Anesthesia Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies / Screening_studies Aspects: Patient_preference Limits: Humans / Infant / Newborn Country/Region as subject: Europa Language: En Journal: Anaesth Crit Care Pain Med Year: 2022 Document type: Article Affiliation country: